AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19834019
Drug: Microplasmin 2
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Microplasmin 2 mg/kg
Trial: 19808128
Drug: Microplasmin 1
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Microplasmin 1 mg/kg followed by infusion of 1 mg/kg
Trial: 19808128
Drug: Microplasmin 1
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Microplasmin 1 mg/kg followed by infusion of 2 mg/kg
Trial: 19808128
Drug: Microplasmin 1
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Microplasmin 1 mg/kg followed by infusion of 3 mg/kg
Trial: 19808128
Drug: Microplasmin 1
RxNorm normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Microplasmin 1 mg/kg followed by infusion of 4 mg/kg
Trial: 11093025
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment for 10 seconds (0.069 ml of ozone)
Trial: 11093025
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment for 20 seconds (0.138 ml of ozone)
Trial: 11093025
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment for 10 seconds on S. mutans
Trial: 11093025
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment for 10 seconds on S. sobrinus
Trial: 9194719
Drug: Oral acyclovir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acyclovir, 400 mg 5 times a day for 3 weeks
Trial: 3923081
Drug: Tube feeding
RxNorm normalized name: BAG,TUBE FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tube feeding during radiation therapy
Trial: 25355728
Drug: Rituximab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (both doses)
Trial: 20196635
Drug: Antagonist group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antagonist group
Trial: 15937757
Drug: PAmAb (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAmAb (0.3, 1.0, and 3.0 mg/kg intramuscular; 1.0, 3.0, 10, 20, and 40 mg/kg intravenous)
Trial: 15937757
Drug: PAmAb (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAmAb (intramuscular and intravenous)
Trial: 15937757
Drug: PAmAb (biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAmAb (biological activity)
Trial: 8641910
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human granulocyte colony stimulating factor (G-CSF) at a dose of 300 micrograms subcutaneously, administered on Friday, Saturday, and Sunday during the radiotherapy period.
Trial: 8641910
Drug: Large-field radiotherapy
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-field radiotherapy without G-CSF (Control group).
Trial: 1503284
Drug: Methohexitone 9
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 9 mg.kg‐1.h‐1 for one hour (group M)
Trial: 1503284
Drug: Methohexitone 9
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 9 mg.kg‐1.h‐1 with fentanyl 7 micrograms.kg‐1.h‐1 for one hour (group MF)
Trial: 6742535
Drug: Flunitrazepam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.02 mg X kg‐1)
Trial: 25327485
Drug: Acarbose 150
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 150 mg/day
Trial: 17072954
Drug: 10% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucrose syrup + levodopa for 3 days (Group 1)
Trial: 17072954
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for levodopa + 10% sucrose syrup for 3 days (Group 2)
Trial: 17072954
Drug: 10% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucrose syrup + levodopa for 7 days (Group 3)
Trial: 17072954
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for levodopa + 10% sucrose syrup for 7 days (Group 4)
Trial: 8501336
Drug: Oral, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with full strength bicarbonate buffer (4 g)
Trial: 8501336
Drug: Oral, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, inactivated whole cell plus recombinant B subunit cholera vaccine with half strength bicarbonate buffer (2 g)
Trial: 8501336
Drug: Full strength
RxNorm normalized name: Dakins Full Strength Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full strength buffer without vaccine
Trial: 8501336
Drug: Half strength
RxNorm normalized name: Dakins Half Strength Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half strength buffer without vaccine
Trial: 3471750
Drug: Imipenem 500
RxNorm normalized name: imipenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 500 mg
Trial: 3471750
Drug: Latamoxef 1
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef 1 g
Trial: 29280043
Drug: Lapatinib, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 2 weeks
Trial: 29280043
Drug: Lapatinib, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib, trastuzumab, or their combination (anti-HER2 therapy) for 18 weeks plus weekly paclitaxel
Trial: 26321318
Drug: Riluzole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (50 mg orally, twice daily)
Trial: 18277878
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group training protocol (exercise therapy, back school, behavioral principles)
Trial: 16547634
Drug: Betamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (8 mg/day)
Trial: 16547634
Drug: Methylprednisolone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (8 mg/day)
Trial: 8356591
Drug: TMP (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP (160 mg)‐SMX (800 mg) twice daily three days per week (group B)
Trial: 8356591
Drug: TMP (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP (160 mg)‐SMX (800 mg) twice daily seven days per week (group C)
Trial: 3306440
Drug: Caroverine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroverine (120 mg/day)
Trial: 3306440
Drug: Meprobamate (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meprobamate (2,400 mg/day)
Trial: 3306440
Drug: Caroverine (2.5-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroverine (2.5-5.0 mg/kg, infusional application)
Trial: 15816793
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg/day in week 1, 16 mg/day in week 2, 24 mg/day in week 3)
Trial: 12873937
Drug: Isoflurane inhaled
RxNorm normalized name: isoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhaled anesthesia
Trial: 11176472
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bethanechol
Trial: 3557757
Drug: Cephradine 2
RxNorm normalized name: cephradine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine 2 g
Trial: 23211012
Drug: Placebo-solution (placebo-group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-solution (placebo-group)
Trial: 19734766
Drug: Tunnelled intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tunnelled intravitreal injection
Trial: 19734766
Drug: Straight intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straight intravitreal injection
Trial: 17392720
Drug: Five-drug cocktail
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug cocktail (Inje cocktail)
Trial: 15042543
Drug: Iron dextran,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran, 1,000 mg IV
Trial: 11556875
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor therapy
Trial: 11717931
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine Zeng Sheng Ping for severe dysplasia
Trial: 11717931
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of riboflavin Calcium for mild dysplasia
Trial: 10150222
Drug: Nisoldipine once
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine once daily (up to 20 mg/day)
Trial: 10150222
Drug: Nisoldipine twice
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine twice daily (up to 20 mg/day)
Trial: 10150222
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (before and after nisoldipine)
Trial: 2574728
Drug: Nisoldipine once
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine once daily
Trial: 29187151
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2.5 μg/kg (group D)
Trial: 29187151
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine 6 mg/kg (group K)
Trial: 29187151
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2 μg/kg and oral ketamine 3 mg/kg (group DK)
Trial: 25924803
Drug: Corticosteroids (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (1 mg/kg/day i.v. methylprednisolone intraoperatively and at postoperative days 1-5)
Trial: 23739650
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/simvastatin 20 mg
Trial: 11473139
Drug: Snapshot methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snapshot methods (same-day telephone interviews or one-off weekly diaries)
Trial: 9409501
Drug: No oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oxygen therapy (Control)
Trial: 7773823
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg in 20 ml NaCl)
Trial: 7773823
Drug: Bupivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (20 ml, 0.375%)
Trial: 7773823
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bupivacaine and morphine
Trial: 7773823
Drug: Saline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (20 ml, control group)
Trial: 344003
Drug: Desoximetasone emollient
RxNorm normalized name: Desoximetasone
DrugBank: Desoximetasone (DB00547)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desoximetasone emollient cream (0.25 percent)
Trial: 344003
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate cream (0.1 percent)
Trial: 22967016
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy during high-dose chemotherapy
Trial: 15616083
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of meperidine (150 mg, range 75-200 mg)
Trial: 10443885
Drug: Initial monthly
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial monthly scanning cohort
Trial: 1905799
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with oral penicillin V
Trial: 1905799
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with placebo followed by penicillin V
Trial: 23317960
Drug: 6-month thrice-weekly
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy
Trial: 23317960
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment up to 9 months
Trial: 23317960
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without additional treatment
Trial: 19243767
Drug: NSAID (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (diclofenac sodium, 25 mg 3 times daily) and omeprazole (20 mg once daily)
Trial: 19243767
Drug: PG (misoprostol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG (misoprostol, 200 microg 3 times daily) with NSAID and omeprazole
Trial: 16739326
Drug: 5'-DFUR (doxifluridine)
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR (doxifluridine) at 800 mg/body daily for 3 years
Trial: 16739326
Drug: 5'-DFUR (doxifluridine)
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR (doxifluridine) at 800 mg/body daily for 1 year
Trial: 16739326
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy with gosereline acetate (3.6 mg/body, monthly) for pre-menopausal patients
Trial: 16739326
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy with tamoxifen (20 mg/day, daily) for post-menopausal patients
Trial: 14710214
Drug: Estramustine phosphate
RxNorm normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine phosphate (EMP) and vinblastine (VBL) combination chemotherapy
Trial: 11846062
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose methotrexate (1 g/m2, day 1), fluorouracil (1.5 g/m2, day 1), leucovorin (15 mg/m2, days 2-4), and doxorubicin (30 mg/m2, day 15), repeated at a 28-day interval, followed by radical surgery
Trial: 3936558
Drug: Sustained-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release formulations of valproic acid (VPA)
Trial: 3936558
Drug: Standard tablet
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tablet of valproic acid (VPA)
Trial: 3936558
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) preparation of valproic acid (VPA)
Trial: 30257756
Drug: 3 PRP
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 PRP injections in the subacromial space at 1-week intervals
Trial: 30257756
Drug: Single depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single depot corticosteroid injection in the subacromial space
Trial: 23672220
Drug: Acarbose chewable
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose chewable tablet
Trial: 23672220
Drug: Acarbose treatment
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose treatment (control group)
Trial: 18279686
Drug: EE-betadex clathrate/drsp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE-betadex clathrate/drsp tablet
Trial: 18279686
Drug: EE/drsp tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/drsp tablet
Trial: 18279686
Drug: Microcrystalline suspension
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline suspension
Trial: 12826042
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5)
Trial: 10855533
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (1.2 pmol/l x kg(‐1) x min(‐1))
Trial: 2004541
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide 400 micrograms once daily
Trial: 2004541
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide 200 micrograms twice daily
Trial: 30107003
Drug: Gemcitabine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine treatment with high pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Trial: 30107003
Drug: High pre-treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Trial: 21277694
Drug: Gemcitabine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine treatment
Trial: 29933533
Drug: Sancai powder
RxNorm normalized name: Sanchi
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sancai powder and Metformin
Trial: 22540957
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (ST) twice/week for 21 weeks (STW)
Trial: 22540957
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (ST) twice/week for 21 weeks (STWx2)
Trial: 22540957
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (STM) twice/week for 21 weeks
Trial: 22540957
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (STMx2) twice/week for 21 weeks
Trial: 8874675
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (AP)
Trial: 1343111
Drug: Felodipine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (oral solution, conventional tablets, extended release tablets)
Trial: 1343111
Drug: Felodipine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (various formulations)
Trial: 29587662
Drug: 0.5% colchicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% colchicine cream for 10 days
Trial: 27515478
Drug: MAL-PDT (methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL-PDT (methyl aminolevulinate photodynamic therapy)
Trial: 27508135
Drug: Apo‐Cetirizine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apo‐Cetirizine 10 mg tablet daily
Trial: 27508135
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen of cetirizine 10 mg tablet, loratadine 10 mg tablet and chlorpheniramine 4 mg tablet, one tablet each day
Trial: 23145952
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg initial dose, then 50 mg IV every 12 hrs)
Trial: 23145952
Drug: Ampicillin-sulbactam (1.5-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam (1.5-3 g IV every 6 hrs) or Amoxicillin-clavulanate (1.2 g IV every 6-8 hrs)
Trial: 23145952
Drug: Ampicillin-sulbactam or
RxNorm normalized name: ampicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam or Amoxicillin-clavulanate
Trial: 18565418
Drug: Best Medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Medical Management with Aspirin (ASA)
Trial: 10457543
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral dose of SR 46349B (5-HT2 antagonist) administered three hours before bedtime
Trial: 8527534
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for 3 days)
Trial: 8527534
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg four times daily for 7 days)
Trial: 2254723
Drug: Regular Treatment
RxNorm normalized name: Midol Regular
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Treatment (RT)
Trial: 6989436
Drug: Early injection
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early injection of insulin (30 minutes before breakfast)
Trial: 6989436
Drug: Late injection
RxNorm normalized name: deoxycholate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late injection of insulin (5 minutes before breakfast)
Trial: 6989436
Drug: Early injection
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early injection of insulin